News:

This week IPhone 15 Pro winner is karn
You can be too a winner! Become the top poster of the week and win valuable prizes.  More details are You are not allowed to view links. Register or Login 

Main Menu

Analysis: Roche stays a step ahead of copycat drugmakers

Started by riky, March 26, 2013, 08:00:20 AM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

riky

Analysis: Roche stays a step ahead of copycat drugmakers

<p><a href="http://news.yahoo.com/analysis-roche-stays-step-ahead-copycat-drugmakers-125855919--finance.html"><img src="http://l2.yimg.com/bt/api/res/1.2/uFvLM1TFQeGpd5X2qNvUyg--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-03-25T125855Z_1_CBRE92O102G00_RTROPTP_2_ROCHE.JPG" width="130" height="86" alt="People enter a factory of Swiss drugmaker Roche in Burgdorf near Bern" align="left" title="People enter a factory of Swiss drugmaker Roche in Burgdorf near Bern" border="0" /></a>By Caroline Copley ZURICH (Reuters) - Delays in developing copies of Roche's top-selling biotech drug are justifying the Swiss company's decision to stay out of biotech generics to focus on improved, patented versions of its medicines. Roche faces its first big test at the end of this year when it loses exclusivity in Europe on MabThera, also known as Rituxan, a treatment for blood cancers and rheumatoid arthritis that had sales of 6.7 billion Swiss francs ($7 billion) in 2012. ...</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login
You are not allowed to view links. Register or Login